PL2532364T3 - Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi - Google Patents

Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi

Info

Publication number
PL2532364T3
PL2532364T3 PL11739865.1T PL11739865T PL2532364T3 PL 2532364 T3 PL2532364 T3 PL 2532364T3 PL 11739865 T PL11739865 T PL 11739865T PL 2532364 T3 PL2532364 T3 PL 2532364T3
Authority
PL
Poland
Prior art keywords
antibodies
treating
pharmaceutical composition
preventing cancer
anti caprin
Prior art date
Application number
PL11739865.1T
Other languages
English (en)
Inventor
Takanori Saito
Fumiyoshi Okano
Shinichi Kobayashi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2532364T3 publication Critical patent/PL2532364T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053Skin, nerves, brain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23Immunoglobulins specific features characterized by taxonomic origin from birds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11739865.1T 2010-02-04 2011-02-04 Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi PL2532364T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010023450 2010-02-04

Publications (1)

Publication Number Publication Date
PL2532364T3 true PL2532364T3 (pl) 2016-11-30

Family

ID=44355511

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11739865.1T PL2532364T3 (pl) 2010-02-04 2011-02-04 Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi

Country Status (16)

Country Link
US (1) US8911740B2 (pl)
EP (1) EP2532364B1 (pl)
JP (1) JP5923985B2 (pl)
KR (1) KR101871704B1 (pl)
CN (1) CN102834113B (pl)
AU (1) AU2011211682B2 (pl)
BR (1) BR112012018948B1 (pl)
CA (1) CA2788545C (pl)
DK (1) DK2532364T3 (pl)
ES (1) ES2583777T3 (pl)
HU (1) HUE030102T2 (pl)
MX (1) MX340016B (pl)
PL (1) PL2532364T3 (pl)
PT (1) PT2532364T (pl)
RU (1) RU2598258C2 (pl)
WO (1) WO2011096517A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0911925B8 (pt) 2008-08-05 2024-02-06 Toray Industries Método para detectar um câncer
PT2322221E (pt) 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
KR101805520B1 (ko) 2010-02-04 2017-12-07 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
ES2583627T3 (es) 2010-02-04 2016-09-21 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer
CA2788716C (en) 2010-02-04 2019-06-18 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
BR112012018943A8 (pt) 2010-02-04 2017-12-19 Toray Industries medicamento e método para o tratamento e/ou prevenção de um câncer
US8709418B2 (en) 2010-02-04 2014-04-29 Toray Industries, Inc. Pharmaceutical composition for treating CAPRIN-1 expressing cancer
PL2532364T3 (pl) 2010-02-04 2016-11-30 Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi
PT2741085T (pt) 2011-08-04 2017-06-30 Toray Industries Método para a deteção de cancro prancreático
HUE030137T2 (en) 2011-08-04 2017-04-28 Toray Industries Pharmaceutical preparation for the treatment and / or prevention of cancer
ES2634249T3 (es) * 2011-08-04 2017-09-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
MX348578B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
RU2624049C2 (ru) 2011-08-04 2017-06-30 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
WO2013018886A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 膵臓癌の治療及び/又は予防用医薬組成物
CA2864999C (en) * 2012-02-21 2020-06-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
EP2818483B1 (en) * 2012-02-21 2017-08-02 Toray Industries, Inc. Medicinal composition for treating and/or preventing cancer
MX360211B (es) 2012-02-21 2018-10-24 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
US9273130B2 (en) 2012-02-21 2016-03-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN104220095B (zh) * 2012-03-30 2016-09-07 东丽株式会社 肝癌的治疗和/或预防用药物组合物
CA2869123C (en) 2012-03-30 2021-03-16 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer
PL2876447T3 (pl) 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
EP2876446B1 (en) 2012-07-19 2018-12-26 Toray Industries, Inc. Method for detecting cancer
EP3031826B1 (en) * 2013-08-09 2018-10-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
EP3533466A4 (en) 2016-10-28 2020-06-10 Toray Industries, Inc. PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND / OR PREVENTION
BR112020019935A2 (pt) 2018-03-30 2021-01-26 Toray Industries, Inc. medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método de tratamento e/ou prevenção do câncer
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
BR112022018166A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
BR112022018161A2 (pt) * 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
US20230139178A1 (en) * 2020-03-12 2023-05-04 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
US20230140155A1 (en) 2020-03-12 2023-05-04 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20220152318A (ko) 2020-03-12 2022-11-15 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
BR112023026992A2 (pt) 2021-06-23 2024-03-12 Toray Industries Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
MX2023014498A (es) 2021-06-23 2024-01-25 Toray Industries Medicamento para el tratamiento y/o prevencion de cancer.
CA3227698A1 (en) 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3227706A1 (en) 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2023008461A1 (pl) 2021-07-27 2023-02-02
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
US20250367307A1 (en) 2022-06-30 2025-12-04 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
AU2023329564A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20250052364A (ko) 2022-08-24 2025-04-18 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
JPWO2024043252A1 (pl) 2022-08-24 2024-02-29
KR20250054778A (ko) 2022-08-30 2025-04-23 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
WO2024048541A1 (ja) 2022-08-30 2024-03-07 東レ株式会社 癌の治療及び/又は予防のための医薬品
KR20250118852A (ko) 2022-12-23 2025-08-06 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
AU2024242849A1 (en) 2023-03-28 2025-09-25 Toray Industries, Inc. Method for detecting cell membrane protein
JPWO2024204685A1 (pl) 2023-03-31 2024-10-03
WO2025058000A1 (ja) * 2023-09-13 2025-03-20 東レ株式会社 癌の治療、予防及び/又は診断用医薬組成物

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
AU752730B2 (en) 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
KR20010083111A (ko) 1998-07-14 2001-08-31 길리스 스티브 전립선암의 치료 및 진단을 위한 조성물 및 방법
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
AU3316600A (en) 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
HK1045332A1 (zh) 1999-04-02 2002-11-22 Corixa Corporation 用於治療和診斷肺癌的化合物及其使用方法
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1224285A4 (en) 1999-10-29 2004-12-08 Human Genome Sciences Inc 27 HUMAN SECRETED PROTEINS
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
JP2004526401A (ja) 2000-03-29 2004-09-02 コリクサ コーポレイション 肺癌の治療および診断のための組成物および方法
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス,インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
WO2002078524A2 (en) 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
CN1789416B (zh) 2001-05-11 2011-11-16 协和发酵麒麟株式会社 含人抗体λ轻链基因的人类人工染色体
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
RU2319709C2 (ru) * 2001-07-17 2008-03-20 Рисерч Дивелопмент Фаундейшн Терапевтические агенты, содержащие проапоптозные белки
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
WO2004097051A2 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
EP2003196A3 (en) 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
PT1735348E (pt) 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
US7858753B2 (en) 2004-03-30 2010-12-28 Glaxo Group Limited Immunoglobulins
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
UA94899C2 (ru) 2005-01-21 2011-06-25 Дженентек, Инк. Фиксированное дозирование антител к her
WO2006089212A2 (en) 2005-02-18 2006-08-24 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
NZ560976A (en) 2005-03-11 2011-06-30 Univ Johns Hopkins Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
WO2007095186A2 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP5083091B2 (ja) 2008-07-24 2012-11-28 大日本印刷株式会社 非接触型データキャリア用導電部材の形成方法及び装置
BRPI0912462B1 (pt) * 2008-08-05 2022-03-22 Toray Industries, Inc Uso de um agente indutor de imunidade, uso de um polipeptídeo e uso de um vetor recombinante
PT2322221E (pt) * 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
BRPI0911925B8 (pt) * 2008-08-05 2024-02-06 Toray Industries Método para detectar um câncer
CA2788716C (en) 2010-02-04 2019-06-18 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
KR101805520B1 (ko) 2010-02-04 2017-12-07 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
BR112012018943A8 (pt) 2010-02-04 2017-12-19 Toray Industries medicamento e método para o tratamento e/ou prevenção de um câncer
PL2532364T3 (pl) 2010-02-04 2016-11-30 Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi
ES2583627T3 (es) 2010-02-04 2016-09-21 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer
US8709418B2 (en) * 2010-02-04 2014-04-29 Toray Industries, Inc. Pharmaceutical composition for treating CAPRIN-1 expressing cancer
WO2013018886A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 膵臓癌の治療及び/又は予防用医薬組成物
PT2741085T (pt) 2011-08-04 2017-06-30 Toray Industries Método para a deteção de cancro prancreático
ES2634249T3 (es) 2011-08-04 2017-09-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer

Also Published As

Publication number Publication date
AU2011211682B2 (en) 2015-08-13
ES2583777T3 (es) 2016-09-22
RU2012137499A (ru) 2014-03-10
CA2788545A1 (en) 2011-08-11
KR101871704B1 (ko) 2018-06-27
BR112012018948B1 (pt) 2021-12-14
JPWO2011096517A1 (ja) 2013-06-13
EP2532364A1 (en) 2012-12-12
KR20120139719A (ko) 2012-12-27
CN102834113B (zh) 2016-03-02
EP2532364B1 (en) 2016-05-04
WO2011096517A1 (ja) 2011-08-11
JP5923985B2 (ja) 2016-05-25
AU2011211682A1 (en) 2012-08-23
CN102834113A (zh) 2012-12-19
BR112012018948A2 (pt) 2020-10-20
DK2532364T3 (en) 2016-08-15
HUE030102T2 (en) 2017-04-28
US8911740B2 (en) 2014-12-16
PT2532364T (pt) 2016-07-28
EP2532364A4 (en) 2013-07-31
MX340016B (es) 2016-06-22
RU2598258C2 (ru) 2016-09-20
US20130071398A1 (en) 2013-03-21
MX2012008997A (es) 2012-09-07
CA2788545C (en) 2019-03-26

Similar Documents

Publication Publication Date Title
PL2532364T3 (pl) Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi
PT3351630T (pt) Composição farmacêutica compreendendo anticorpos anti caprin-1 para tratar e/ou prevenir o cancro
PL2532366T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
PL2532680T3 (pl) Kompozycja medyczna do leczenia raka i/lub zapobiegania
PL2740793T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
PL2818483T3 (pl) Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
PL2740795T3 (pl) Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
PL2740798T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworom
PL2532365T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
PL2532743T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka
IL267342A (en) Antibodies and preparations containing them for the treatment of cancer
IL225471A0 (en) Preparations and methods for the prevention and treatment of cancer
BR112012018943A8 (pt) medicamento e método para o tratamento e/ou prevenção de um câncer
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
PL2832365T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby
PT2818481T (pt) Composição farmacêutica para tratamento e/ou prevenção de cancro
SG10201500124VA (en) Methods and Compositions for Treating Cancer
IL251083B (en) Compounds and preparations for the treatment of cancer
EP2651443A4 (en) ANTI-CCL25 AND ANTI-CCR9 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND THE MIGRATION OF CANCER CELLS
IL224545A (en) Combined Pharmaceuticals for the Treatment and Prevention of Infectious Diseases
IL226095A0 (en) The history of pyridine and its use in pharmaceutical preparations for the treatment of cancer
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
EP2537031A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP2902027A4 (en) ACTIVE COMPOSITION FOR THE TREATMENT OF TUMORS AND THE USE THEREOF
AU2011211693B2 (en) Pharmaceutical composition for treating and/or preventing cancer